ABSTRACT
INTRODUCTION
According to the united nations program on HIV/AIDS (UNAIDS), more than 45 million people have been infected with the human immunodeficiency virus (HIV) since the first case was described in 1981. Over 90% of HIV infected people live in developing countries. The AIDS epidemic has resulted in a tremendous cost in terms of loss of lives and life-quality worldwide, especially in Africa, where 70% of deaths from HIV-1 infection have occurred (UNAID and WHO 2007) . There is an emerging consensus that the HIV epidemic in the developing world requires treatment with antiretroviral drugs (Gange et al., 2003) . In wellresourced settings, the decision to initiate ART is based predominantly on the presence of HIV-related symptoms and on CD4+ T-cell count (Badri and Wood 2003) . Absolute CD4+ T-cell counts and CD4+ percentages have constituted the mainstay criteria for monitoring progression in HIV-1 infected patients. CD4+ T-cell counts < 200 cell/mm3 or a CD4+ percentage < 20% is associated with an increased risk for Pneumocystis jiroveci pneumonia or infection with other opportunistic pathogens (Badri and Wood 2003) .
Monitoring individuals with HIV infection/AIDS requires the use of expensive tools, which are not readily available in resource-limited settings (Akinola et al., 2004) . The identification of laboratory tests that help the clinician to predict progression is useful not only to monitor the patients' disease evolution but also to define the right time to initiate treatment (WHO 2005) . In 2003, WHO recommended the use of absolute lymphocyte count as an alternative marker when a CD4+ cell count is not available or is not affordable. And recommended that a total lymphocyte count of ≤ 1200 lymphocytes/mm3 can be substituted for the CD4 count when the later is unavailable and HIV-related symptoms existed. One challenge for using TLC for predicting the disease stage is that it does not linearly decrease over time during HIV infection, but rather there is a period of stability, followed by a faster decay that precedes clinically-defined AIDS (Gange et al., 2003) .
This research was design to assess the level of CD4 cell count and total lymphocyte count in the HIV positive (tests) and HIV negative (controls), also to assess the relationship between CD4 cell count and TLC and to compare our findings with those obtainable in other part of the world.
MATERIALS AND METHODS
The study was conducted at laboratory department of Infectious Diseases Hospital (I.D.H.) Kano. Two hundred and fourty four (244) newly diagnosed HIV seropositive (tests) individuals (112 males and 132 females) distributed among 4 age groups (20-30: 89, 31-40: 96, 41-50: 43, 51-60: 16) and fifty (50) apparently healthy http://dx.doi.org/10.4314/bajopas.v6i2.18 HIV seronegative (controls) individuals (21 male and 39 females) distributed among 4 age groups (20-30: 34, 31-40: 10, 41-50: 4, 51-60: 2) were enrolled in this study. A 5ml whole blood sample from each patient was collected in EDTA vacutainer tubes in the morning between 8:00am to 10:00am. The Total CD4+ T Lymphocytes was determined using an automated flow cytometer (Partec Cyflow Counter 060727120, Germany). The blood samples were processed and analyzed within six hours from the time samples were collected. And the total lymphocyte were obtained from Full Blood Count results, using an Automated Hematology Analyzer (Sysmex KX-21N, Sysmex Corporation. Results obtained were analyzed using SPSS 14.0 for windows.
RESULTS
The results obtained in this study are expressed as mean + SEM (Standard error of mean) for the control and the test individuals respectively. These are presented in Tables 1 -4 ) (p<0.01). This was due to the facts that CD4+T lymphocyte are specifically targeted by HIV which results in linear reduction in CD4 count. A spearman's correlation study was done between the CD4 counts and TLC, there was a slightly positive correlation (r= 0.586) in the test and strong positive correlation in control (r = 0.739).
DISCUSSION
Considering the above resuls this work agrees with the findings of Gange et al., (2003) , Johnson et al., (2009) and Akinola et al., (2004) : Gange et al (2003) reported that total lymphocyte count does not linearly decrease over time during HIV infection, but rather there is period of stability followed by a faster decay that precedes clinically defined AIDS. Johnson et a.l, (2009) reported that low absolute lymphocyte count does not correlate with the severe immune suppression based on CD4 cell count, it also does not improve ability to identify children in need of ART. Akinola et al., (2004) and Vand Der Ryst et al., (1998) found that TLC is not a good predictor of the CD4+ T-cell count. This work disagree with the work of Fournier and Sosenko (1992) and Blatt et al., (1993) . Fournier and sosenko (1992) stated that total lymphocyte count has a clinical utility as a predictor of AIDS stage. Blatt et al., (1993) reported that TLC was a useful indicator of significant immune suppression.
COCLUSION
Total lymphocyte count could not be used alone as an alternative to CD4 count in initiating ART, but in conjunction with clinical sign and symptoms.
RECOMMENDATION
It could therefore be recommended that larger number of patients be used and other factors that affect immune system like nutritional status and presence or absence of coinfection be considered.
